All In Biotech

Drug Trial Radar · NCT02475629

Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV

A Phase 3, Single Arm, 24-Week, Multicenter Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant HIV-1

Last checked: Nov 20, 2026Latest source record: Mar 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

40

Actual

Start

Aug 2015

Primary completion

Oct 2016

Study completion Dec 2016

Sponsor

Lead sponsor
TaiMed Biologics Inc.Industry
Sponsor type
Industry
First posted
Jun 19, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3, single arm, multicenter study will evaluate the safety and effectiveness of ibalizumab in treatment-experienced patients infected with multi-drug resistant HIV-1.

Conditions

  • HIV

Interventions

  • ibalizumabBiological

    2000mg intravenous ibalizumab (loading dose), followed 14 days later by 800mg intravenous ibalizumab every 2 weeks

  • Optimized Background Regimen (OBR)Drug

    All participants will be prescribed an Optimized Background Regimen of antiretroviral medications selected on the basis of treatment history and the results of Screening viral resistance and tropism testing. The prescribed regimen must contain at least one agent to which the participant's virus is known to be sensitive.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy: Proportion of Participants Achieving a Viral Load Reduction of at Least 0.5 Log 10: ITT-MEFTime frame: Day 14
  2. Efficacy: Proportion of Subjects With a Viral Load Decrease of at Least 0.5 Log 10 - Protocol CorrectTime frame: Day 14

Locations

30 sites in 3 countries. Site status is shown where the registry gives one.

  • Long Beach Education and Research Consultants

    Long Beach, California

  • W King Health Care Group

    Los Angeles, California

  • Southern California Permanente Medical Group

    Los Angeles, California

  • Ruane Medical and Clinical Research Institute

    Los Angeles, California

  • Charles R. Drew Univ. of Med. & Science Clinical and Translational Research Center

    Los Angeles, California

  • Anthony Mills, MD, Inc.

    Los Angeles, California

  • AIDS Healthcare Foundation

    Los Angeles, California

  • Palmtree Clinical Research Inc.

    Palm Springs, California

  • Quest Clinical Research

    San Francisco, California

  • Kaiser Foundation Research Institute

    San Francisco, California

  • Yale University

    New Haven, Connecticut

  • Circle Care Center, LLC

    Norwalk, Connecticut

  • Georgetown University School of Medicine

    Washington D.C., District of Columbia

  • Gary Richmond, MD, PA

    Fort Lauderdale, Florida

  • Midway Immunology and Research Center

    Ft. Pierce, Florida

  • University of Miami

    Miami, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • Triple O Research Institute

    West Palm Beach, Florida

  • AIDS Research Consortium of Atlanta

    Atlanta, Georgia

  • University of Maryland, Institute of Human Virology

    Baltimore, Maryland

  • Henry Ford Health Systems

    Detroit, Michigan

  • St. John Hospital and Medical Center

    Southfield, Michigan

  • ACRIA

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Carolinas HealthCare System

    Charlotte, North Carolina

  • North Texas Infectious Disease Consultants

    Dallas, Texas

  • Research Access Network

    Houston, Texas

  • Clinical Research PR, Inc

    San Juan, Puerto Rico

  • E-Da Hospital

    Kaohsiung City, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.